The carcinostatic activity of 5-hydroxy-2-formylpyridine thiosemicarbazone.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000818:Animals; D001853:Bone Marrow / Q000473:pathology; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000473:pathology; D055598:Chemical Phenomena; D002621:Chemistry; D005260:Female; D006367:HeLa Cells / Q000201:enzymology; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007939:Leukemia L1210 / Q000188:drug therapy / Q000473:pathology; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D012510:Sarcoma 180 / Q000188:drug therapy / Q000473:pathology; D013882:Thiosemicarbazones / Q000008:administration & dosage* / Q000138:chemical synthesis
D013882:Thiosemicarbazones